Summary
The outcomes of thromboprophylactic trials have been debated for decades. Recently,
the 9th edition of the American College of Chest Physicians (ACCP) evidence-based clinical
practice guidelines based their strong recommendations only on patient-important outcomes.
Practically, symptoms were considered the crucial element. Consequently, studies that
primarily aimed at reducing venographic thrombi were considered less pertinent than
studies that focused on symptomatic thrombosis. In the present viewpoint, we challenge
the argument that “symptomatic” and “clinically relevant” are interchangeable. In
particular, the case is made that asymptomatic events may be clinically relevant and
that asymptomatic venographically detected thrombosis is a clinically relevant surrogate
outcome for fatal pulmonary embolism.
Keywords
Prophylaxis - pulmonary embolism - thrombosis - surgery